Volume 50, Issue 6 pp. 1263-1265
Brief Report

Congenital amegakaryocytic thrombocytopenia: The diagnostic importance of combining pathology with molecular genetics

Melissa J. Rose DO

Melissa J. Rose DO

Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio

Division of Hematology/Oncology/BMT, Children's Hospital, Columbus, Ohio

Search for more papers by this author
Kathleen K. Nicol MD

Kathleen K. Nicol MD

Department of Pathology, The Ohio State University College of Medicine, Columbus, Ohio

Division of Pathology, Children's Hospital, Columbus, Ohio

Search for more papers by this author
Micah A. Skeens RN, MS, CPNP, CPON

Micah A. Skeens RN, MS, CPNP, CPON

Division of Hematology/Oncology/BMT, Children's Hospital, Columbus, Ohio

Search for more papers by this author
Thomas G. Gross MD, PhD

Thomas G. Gross MD, PhD

Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio

Division of Hematology/Oncology/BMT, Children's Hospital, Columbus, Ohio

Search for more papers by this author
Bryce A. Kerlin MD

Corresponding Author

Bryce A. Kerlin MD

Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio

Division of Hematology/Oncology/BMT, Children's Hospital, Columbus, Ohio

Columbus Children's Hospital, 700 Children's Drive, Columbus, OH 43205.===Search for more papers by this author
First published: 31 January 2008
Citations: 31

Abstract

Congenital Amegakaryocytic Thrombocytopenia (CAMT) is a rare bone marrow failure syndrome that presents with isolated thrombocytopenia within the first year of life. Classic diagnostic bone marrow findings reveal absent or significantly decreased megakaryocytes with otherwise normal marrow cellularity. We present a newborn with thrombocytopenia whose initial bone marrow aspirate showed an appropriate number of megakaryocytes. CAMT was subsequently diagnosed after molecular testing demonstrated a mutation in the thrombopoietin receptor. The presence of a normal number of megakaryocytes on an initial bone marrow aspirate should not exclude CAMT from the differential diagnosis of thrombocytopenia within the first year of life. Pediatr Blood Cancer 2008;50:1263–1265. © 2008 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.